Business Context and Reporting Period
This Form 8-K is filed by Aerpio Pharmaceuticals, Inc. (not Whitehawk Therapeutics, Inc.) on May 16, 2017. The filing serves to announce the company's financial results for the quarter ended March 31, 2017. The registrant is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes
The filing does not detail specific material changes versus the prior comparable period. It solely references the announcement of the Q1 2017 results.
Guidance, Outlook, and Risks
Management commentary, guidance, outlook, risks, contingencies, and unusual items are not detailed in the body of this Form 8-K. The document states that the information is furnished and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in Exhibit 99.1 (the press release dated May 16, 2017).
- Confirm the company name is Aerpio Pharmaceuticals, Inc., as the input metadata incorrectly listed Whitehawk Therapeutics, Inc.
- Review the full press release for any updates on clinical trial progress or regulatory milestones not captured in this summary.
- Note that the financial data in this 8-K is not legally "filed" under Section 18 of the Exchange Act.